Evolution of the Average Target: UCB

Evolution of the Average Target - UCB

Evolution of the Target Price: UCB

Evolution of the Target Price - UCB

Changes in Analyst Recommendations: UCB

452dfe2b7c.qd0qw5aAlGUaZjMI6fnGA-e9H6FrF1u4oQbgRPYZ6Ag.4ppIr9zywghqAms6nJ6PZbX0VM4zJjPozla6B6Zz31jGqEGl9MT9CFhSBw~d20f8b4e3104e03ff2dd1216972c0188
Nov. 06 Berenberg Sees 'Sustainable' Volume-led Growth for UCB into FY27; Estimates Up MT
Oct. 27 AlphaValue/Baader Europe Raises Estimates for UCB on Recent FY26 Outlook Upgrade MT
Oct. 26 UCB: Undercommit and overdeliver – The UCB way Alphavalue
Oct. 26 A Week of Reckoning for Wall Street Zonebourse
Oct. 26 BofA Lifts UCB Price Objective, EPS Forecasts After 'Surprise' FY26 Guidance Upgrade MT
Oct. 23 AlphaValue/Baader Europe Downgrades UCB to Reduce MT
Oct. 22 UCB: Growth engine isn't out of breath yet Alphavalue
Oct. 22 UCB raises guidance on strength of its two flagship treatments, analysts applaud Zonebourse
Oct. 21 BofA: UCB's Bimzelx Sets 'Very High' Bar Ahead of Q4 Competitor Data in Hidradenitis Suppurativa MT
Oct. 16 FDA green light for UCB and positive view from DB Zonebourse
Sep. 24 BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug MT
Sep. 24 BofA Securities Keeps UCB at Buy MT
Sep. 11 AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up MT
Sep. 10 UCB: A rare window of affordability Alphavalue
Aug. 20 Cancer vaccines finally garner the spotlight Alphavalue
Aug. 18 UCB: An unimpressive upgrade-led correction opens a rare opportunity Alphavalue
Aug. 11 Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed MT
Aug. 11 UCB barely moves despite positive calls from ING and Berenberg Zonebourse
Jul. 31 AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT MT
Jul. 30 Kempen Upgrades UCB to Buy Rating, Boosts PT MT
Jul. 14 Where would AI lead Pharma in the long run? Alphavalue
Jul. 03 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
Jun. 22 UBS Trims UCB's PT, Affirms Buy Rating MT
Jun. 15 UCB Slumps Following Analyst Downgrade Zonebourse
Jun. 15 Barclays Downgrades UCB to Equalweight, Trims PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1.03%
+7.34%
+1.15%
+6.64%
+1.08%
+10.08%
-6.85%
+15.51%
-6.66%
+4.72%
Average +3.40%
Weighted average by Cap. +4.45%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
298.80EUR
Average target price
293.89EUR
Spread / Average Target
-1.64%
High Price Target
340.00EUR
Spread / Highest target
+13.79%
Low Price Target
208.00EUR
Spread / Lowest Target
-30.39%

Analyst Consensus Detail

Analyst consensus - UCB

Consensus revision (last 18 months)

Consensus revision (last 18 months) - UCB
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB